IRVINE, Calif., Nov. 12, 2012 /PRNewswire/ -- When most American women aged 25 and up look in the mirror these days, most can find one or two things they would like to improve about their appearance. In fact, according to a new survey of over 1,000 American women commissioned by Syneron Medical, the pioneer and market leader in body shaping technologies, fewer than one in ten women (8 percent) are very satisfied with their current appearance1. So what improvements on the face or body ranked the highest on women's wish list today? Seven in ten (70 percent) women admit they are most worried about developing a tummy bulge now and in the future (66 percent), as opposed to long reigning champion - wrinkles and/or fine lines, now (50 percent), and in the future (57 percent)2.
"It has been a long-held belief that a flawless complexion represents youth and beauty. With the rise of pop culture and the focus on shapely bodies, this perception has shifted beyond a perfect face to include the perfect body as well," said Tina Alster, M.D., board-certified dermatologist and director of the Washington Institute of Dermatologic Laser Surgery in Washington, D.C. "Fortunately, most American women today are conditioned to believe that living a healthy lifestyle yields many rewards in appearance, both for the face and the body. But for many women, despite avoidance of carbs and regular exercise, there remain certain body areas that still trouble them. Losing that last inch or two – from the muffin tops or saddle bags – can really boost a woman's confidence—that's where treatments like VelaShape® can help."
American women's perception of their bodies is a year round concern, in or out of clothes. In fact, 73 percent of ladies admit that if they were to come into some money, they would be more likely to invest in a better body shape before a designer wardrobe3. "Having designed luxury apparel for women of all shapes and sizes for over thirty years, my designs accentuate a woman's best assets while minimizing flaws," says Rickie Freeman, founder and CEO of Teri Jon®, known for her collection of timeless curve-hugging special occasion dresses. "Even the most beautiful gown won't make a difference if you're not confident in your own body."
Together VelaShape® and Rickie Freeman have partnered to introduce the Little Vela Dress (LVD) Campaign to empower women to feel confident in the most fashion forward wardrobe staple for the holidays: the little black dress. "The Little Black Dress is so versatile, it can take you from a power breakfast through the day and into a night on the town with style," says Rickie. "The Little Black Dress is a timeless style that appeals across many generations. Today the LBD is often cut shorter and fits tighter. VelaShape® can help women love their bodies even more."
During the LVD campaign, VelaShape® will host a "Little Vela Dress Facebook Makeover Contest." Participants will be asked to take a picture of themselves in their own Little Black Dress and tell VelaShape® what areas of their body they love—and which ones they'd like to improve - to transform their LBD into the perfect LVD.
The contest begins Monday, November 12 and ends Sunday, November 30, 2012. One lucky grand prize winner will be selected at the end of the contest to win a series of four customized VelaShape® treatments with a premier Syneron physician. The winner will also be awarded a trip to New York City to meet Rickie Freeman of Teri Jon® in her glam showroom where she will receive a customized Little Vela Dress fitted just for her. Finally, the contest will include a makeover – hair and makeup – done by a celebrity stylist and will conclude with a professional photo shoot. The total prize package is valued at $5,000. Ten lucky runners-up will also be chosen at random to win a $100 gift card to shop at www.terijon.com. All winners will be announced Monday, December 1.
About VelaShape® It's estimated that anywhere from 85 percent to 98 percent of women over the age of 16 have cellulite. A recent survey of American women 25 and up identified their tummy bulge (70 percent) as their #1 concern followed by muffin top (55 percent) and cellulite (45 percent)4. VelaShape is the non-surgical alternative that's clinically proven to temporarily reduce the appearance of cellulite while smoothing and shaping the areas that diet and exercise can't quite fix. With over 500,000,000 million media impressions, over 10,000 procedures performed every day and over 40 published clinical studies, VelaShape® remains the trusted technology for cellulite and non-surgical body shaping by physicians, beauty experts and millions of patients worldwide.
About Syneron Medical Ltd. Syneron Medical Ltd. – a company devoted to real technology, real science and real results – is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. The Company's aspiration and commitment to innovation expands Syneron's offering beyond medical device into the largest in-demand applications in beauty - skin lightening. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide. Additional information can be found at www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that the merger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.
In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.
1 Women Survey by Kelton, October 2012, Slide 2 2 Women Survey by Kelton, October 2012, Slide 4 3 Women Survey by Kelton, October 2012, Slide 3 4 Women Survey by Kelton, October 2012, Slide 4